Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. More specifically, Evotec France is unique within Evotec since it includes all activities and expertise for preclinical R&D of small molecule drugs, primarily in the field of oncology and cardiovascular diseases and a team dedicated to translation to the clinic, directly interacting with University Cancer Institute of Toulouse, largest oncology focused hospital in Europe. With more than 10 years of experience in biotech, and being in charge of many projects mainly related to sterol and lipid metabolism in health and disease, Michaël is involved in management of the oncology portfolio in Evotec.
Evotec France
Building 16 – C2203
195, route d’Espagne
31036 Toulouse
France
As part of our MSCA-ESR training on complementary skills we got to leave the wet lab to explore what happens on the other side of the bench and to learn what it means to be a scientific editor. This is our story.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
